Iovance Biotherapeutics Inc  

(Public, NASDAQ:IOVA)   Watch this stock  
Find more results for IOVA
+0.55 (3.16%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.40 - 18.30
52 week 4.45 - 18.30
Open 17.40
Vol / Avg. 0.00/1.33M
Mkt cap 1.53B
P/E     -
Div/yield     -
EPS -1.31
Shares 85.00M
Beta 6.20
Inst. own 74%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -56.95% -38.12%
Return on average equity -60.32% -75.55%
Employees 51 -
CDP Score - -


999 Skyway Rd Ste 150
SAN CARLOS, CA 94070-2724
United States - Map
+1-650-2607120 (Phone)
+1-302-7301370 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.